Are aceminib and orebatinib the same drug? what's the difference

Asciminib (Asciminib) andOlverembatinib (Olverembatinib) are both targeted drugs used to treat chronic myeloid leukemia (CML) and other related diseases, but they belong to different drug classes with their own unique mechanisms of action and indications.

Asiminib is a new type of tyrosine kinase inhibitor (TKI). It is the first BCR::ABL1 inhibitor targeting the myristoyl pocket (STAMP) of ABL1. Unlike traditional TKIs, aceminib does not inhibit the activity of ABL kinase by competing for ATP binding, but directly binds to the myristoyl pocket of ABL1, inducing the kinase to transition to an inactive conformation. This mechanism makes Asiminib effective against many common resistance mutations, especially the T315I mutation, which is a major challenge in traditional TKI therapy. In addition, Aceminib performs well in terms of selectivity, and its target is relatively specific, which can significantly reduce interference with other normal signaling pathways, thereby reducing side effects.

In contrast, orebatinib is a new type of small molecule oral3G BCR-ABL1 inhibitor designed using a scaffold hopping strategy to ultimately form an extensive donor-acceptor hydrogen bond network. This innovative TKI exhibits potent in vitro inhibitory activity (IC50 0.5nM) against both wild-type and mutant BCR-ABL1 and enhances cell cycle arrest and apoptosis of CML cells. In studies in xenograft and allograft animal models, orebatinib also induced degeneration of subcutaneous CML cells expressing wild-type and mutant BCR-ABL1, including T315I.

In terms of efficacy, both aximinib and orebatinib have shown good clinical effects, but the specific efficacy and tolerability may vary depending on individual patient differences. Clinical studies have shown that aceminib can achieve a higher rate of complete remission and maintain a good safety profile after long-term use. However, due to the broad spectrum of orebatinib, it may exhibit greater resistance to mutations in certain complex cases.